Home Featured Page 267

Featured

Latest

The Problems We Will Be Lucky to Have

Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date

Is It Worth It? What Colorado’s Early Experience With Regulated Psychedelic Care Has the Field Asking, and What To Do About It

Compass Says NDA Will Be Filed Within Two Weeks, Declines to Comment on Usona

Podcast: Usona Files Psilocybin Application, We Review 610 Comments Submitted to FDA, and FDA Approves NRx’s Generic Ketamine

Book Review: Alexander Shulgin’s The Nature of Drugs

Nova Mentis Autism Clinical Study Approved by Canadian Institutional Review Board

MYND Life Sciences Expands Intellectual Portfolio to Target Alzheimer’s disease and...

Awakn Life Sciences to Commence Trading on the NEO Exchange under...

MindMed Appoints MGH Psychiatrist-in-Chief Dr. Maurizio Fava to Scientific Advisory Board

COMPASS Pathways becomes Founding Supporter of the British Neuroscience Association’s inaugural...

Filament Health Corp. Announces Approval for Listing on the Neo Exchange

PsyBio Therapeutics Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds including...

Cybin Announces Completion of its 51st Pre-Clinical Psychedelic Molecule Study

Interview: Dr. Josh Woolley (TrPR) and Ben Lightburn (Filament Health)

EDITOR PICKS

The Problems We Will Be Lucky to Have

Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House...

Is It Worth It? What Colorado’s Early Experience With Regulated Psychedelic...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

The Problems We Will Be Lucky to Have

Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date

Is It Worth It? What Colorado’s Early Experience With Regulated Psychedelic Care Has the Field Asking, and What To Do About It

Compass Says NDA Will Be Filed Within Two Weeks, Declines to Comment on Usona

Podcast: Usona Files Psilocybin Application, We Review 610 Comments Submitted to FDA, and FDA Approves NRx’s Generic Ketamine

Book Review: Alexander Shulgin’s The Nature of Drugs

Nova Mentis Autism Clinical Study Approved by Canadian Institutional Review Board

MYND Life Sciences Expands Intellectual Portfolio to Target Alzheimer’s disease and...

Awakn Life Sciences to Commence Trading on the NEO Exchange under...

MindMed Appoints MGH Psychiatrist-in-Chief Dr. Maurizio Fava to Scientific Advisory Board

COMPASS Pathways becomes Founding Supporter of the British Neuroscience Association’s inaugural...

Filament Health Corp. Announces Approval for Listing on the Neo Exchange

PsyBio Therapeutics Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds including...

Cybin Announces Completion of its 51st Pre-Clinical Psychedelic Molecule Study

Interview: Dr. Josh Woolley (TrPR) and Ben Lightburn (Filament Health)

EDITOR PICKS

The Problems We Will Be Lucky to Have

Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House...

Is It Worth It? What Colorado’s Early Experience With Regulated Psychedelic...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY